Securities Code: 002898
Securities Abbreviation: Sailong Delisting
Announcement Number: 2026-080
Sailong Pharmaceutical Group Co., Ltd.
Eighth Risk Warning Announcement on the Company's Stock Entering the Delisting Transaction Period
The Company and the entire Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.
Special Risk Warning:
-
Sailong Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") will be delisted on the next trading day after the delisting transaction period ends, and the Company's stock will be terminated from listing.
-
The Company's stock resumed trading and entered the delisting transaction period on June 26, 2026. The delisting transaction period is fifteen trading days, with the expected last trading day being July 16, 2026. This announcement is disclosed on the fifteenth trading day. Upon the expiration of the trading period, the Company will be delisted. Investors are urged to invest prudently and be aware of the risks.
-
During the delisting transaction period, the Company will not plan or implement any major asset restructuring.
-
Investors, securities companies, and other market participants are advised to promptly settle stock pledge repurchase, agreed repurchase, margin financing, securities lending, and other related businesses before the stock delisting.
-
For judicial freezing businesses that expire after the stock delisting and before the initial registration period of the two-network company and delisted company segments managed by the National Equities Exchange and Quotations Company Limited (hereinafter referred to as the "Delisting Segment") is completed, it is recommended that the relevant authorities complete the renewal of the freezing procedures through the original assisting execution channels before the stock delisting.